Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Total Monthly Retail + Institutional Data January-2017
ATH ACROSS THE BOARD IN MARKET SHARE
V
TRx: 86,096 {vs 90,234; -4.59%} -- Sector -6.05% -- (2nd ATH Number)
(Inst # 3,410 vs 3,955)
Gen L
TRx: 267,285 {vs 285,408; -6.35%}
(Inst # 21,425 vs 21,538)
L
TRx: 9,127 {vs 10,208; -10.59%}
(Inst # 1,333 vs 1,279)
V Monthly Retail + Inst. TRx Market Share: 23.75% vs 23.39% --- ATH
V Monthly Retail + Inst. NRx Market Share: 26.25% vs 25.31% --- ATH
V Monthly Retail + Inst. Ref Market Share: 22.38% vs 22.38% --- ATH
Scripts Update for Week Ending 10/02
ATH Across the Board in Terms of Market Share
ATH Once Again for NRx
V
TRx: 19,602 {vs 19,462; +0.72%} Sector -1.48%
NRx: 8,348 {vs 8,278; +0.85%} Sector -0.74% -- ATH
Ref: 11,254 {vs 11,184; +0.63%} Sector -1.96%
GenL
TRx: 54,781 {vs 56,056; -2.27%}
NRx: 21,314 {vs 21,617; -1.40%}
L
TRx: 1,675 {vs 1,683; -0.48%}
NRx: 592 {vs 584; +1.37%}
V TRx Market Share: 25.77% vs 25.21% -- ATH
V NRx Market Share: 27.59% vs 27.16% -- ATH
V Ref Market Share: 24.57% vs 23.94% -- ATH
CitiGroup Report
Published 05/02/2017
AMGN's PCSK9 Outcomes & SMid Biotech
FOURIER Trial Success Positive for MDCO, ESPR & AMRN
Conclusion(s) – On Friday MDCO, ESPR & AMRN shares gained after AMGN reported its PCSK9 outcomes trial FOURIER met its primary endpoint. Below we discuss the impact on each of these stocks. In general, we agree that FOURIER's success is a positive for these 3 stocks, but wonder whether the relatively large gains were overdone given that FOURIER was widely expected to succeed.
MDCO: FOURIER Positive for All PCSK9 Agents, Including Inclisiran – On
Friday MDCO increased 21% to a mkt cap of $3.3B. Positive FOURIER results are derisking for MDCO since inclisiran is in the same class as AMGN's Repatha....
ESPR: FOURIER + Trump Administration a Positive Combo – On Friday ESPR increased 29% to a mkt cap of $371M. The enterprise value more than doubled from ~$80M to ~$164M. We agree that the FOURIER result is positive for ESPR, particularly because FDA could be more willing to approve bempedoic acid based on LDL lowering without the need for outcomes results at the time of approval. However, we believe regulatory risk is could be a long-term overhang for ESPR, with no clear answer as to whether FDA will accept LDL as a surrogate biomarker until after the NDA filing in 2019....
AMRN: FOURIER Even Positive for Triglyceride-Lowering Drug Vascepa – On Friday AMRN increased 6% to a market cap of $843M. We see less readthrough from FOURIER to AMRN than the other stocks because AMRN's drug is mainly focused on lowering triglycerides (TGs) instead of LDL. However, with that being said, we see the following points to consider
1) FOURIER's finding that outcomes can be improved when adding an agent on top of a statin is encouraging sign for the REDUCE-IT outcomes trial of Vascepa on top of a statin (results in early 2018)
2) FOURIER supports that lower LDL is better, which supports that Vascepa's 6.2% LDL reduction should favorably contribute to REDUCE-IT outcomes results (we estimate a 6% LDL reduction could provide a ~3.5% relative risk reduction beyond the benefit from TG lowering and Vascepa's other benefits)
3) FOURIER could increase focus on LDL as a biomarker, which could be favorable for Vascepa marketing efforts since competitor Lovaza increases LDL by 3.5% per its label.
Amarin Corp
Valuation
Our $5 target price for AMRN is based on using a DCF valuation with a 12% discount rate and 2% terminal growth rate. We model through 2030 and project peak sales for Vascepa of $173M in 2018 for the currently approved indication, and peak sales of $2.4B in 2024 if REDUCE-IT is successful and the label is expanded.
We probability-weight sales of Vascepa in the REDUCE-IT indication @ 30%. We assume peak penetrations for Vascepa of just 2.5% in both the current and REDUCE-IT indications (compared to ~1.7% currently for Vascepa in just the current indication).
Risks
We rate AMRN High Risk given the historical and anticipated volatility in stock price that is common for biotech stocks.
In addition, we see the following downside risk to the shares acheiving our target price:
Clinical Risk - Failure of the REDUCE-IT outcomes trial
Commercial Risk - Lower than expected sales of Vascepa
Competitive Risk - Superior results or execution from competitors with triglyceride lowering agents
Intellectual Property Risk - Vascepa losing exclusivity closer to 2020 (end of 30 month stay after NCE and expiration of strongest patent) than 2030 (expiration of latest patents)
Regulatory Risk - Failure of FDA to expand Vascepa's label as wide as expected if REDUCE-IT is successful (though AMRN does have a SPA agreement that should reduce, but not eliminate, this risk)
bblack,
True that, i missed that they were holding 12,500,000 PRN
Thanks for the mention and i agree with your thesis
INVEST,
I did but you never got my point;
There you go again;
Both never had a position in AMRN before. Their 1st buy was in the 3rd quarter and they liquidated all in the last quarter, this shows that they got in to profit from an expected price increase, or they drove this increase in order to enhance the performance of their funds.
In Q3, low price was 2.11
In Q4, high price reached 3.65
So do the math and possible or approximate average price of entry and exit and you will conclude to high extent the reason of them buying into amarin was to realize a quick quarter profit and enhance fund's performance in year end.
Totally wrong INVEST
Just for the records both Franklin Resources & Perceptive Advisors initiated a new position in AMRN in their release as of Sep-2016. During that quarter the low price of AMRN was 2.11 in 07-2016 and high of 3.46 in 08-2016
Having liquidated their position for a total of ~ 6.2 million share as of Dec-2016 means they got a position to enhance their fund's return by year end. During the last quarter AMRN high was 3.65 in 10-2016 which proves the point of showing positive fund return / enhancing the return of their fund's performance.
So please do not flip the story the way it suits you by throwing comments such as "disheartening and a wonderment to see such big sells at this stage in the game"
Thank you
Jan-2017 vs. Jan-2016 (Retail Data ONLY Comparison)
V
TRx: 82,686 {vs 54,111; +52.81%} – Sector +2.17%
NRx: 33,732 {vs 21,884; +54.14%} – Sector +2.76%
Ref: 48,954 {vs 32,227; +51.90%} – Sector +1.80%
Gen L
TRx: 245,860 {vs 261,606; -6.02%}
NRx: 92,065 {vs 98,640; -6.67%}
L
TRx: 7,794 {vs 13,485; -42.21%}
NRx: 2,717 {vs 4,530; -40.02%}
V Jan-2017 Retail ONLY TRx Market Share: 24.58% vs 16.44% in Jan-2016
V Jan-2017 Retail ONLY NRx Market Share: 26.25% vs 17.50% in Jan-2016
Total Monthly Retail ONLY Data January-2017
ATH Across the Board in terms of Market Share
V
TRx: 82,686 {vs 86,279; -4.16%} – Sector -12.83%
NRx: 33,732 {vs 33,420; +0.93%} – Sector -2.66% -- ATH
Ref: 48,954 {vs 52,859; -7.38%} – Sector -8.46%
Gen L
TRx: 245,860 {vs 263,870; -6.83%}
NRx: 92,065 {vs 95,402; -3.50%}
L
TRx: 7,794 {vs 8,929; -12.71%}
NRx: 2,717 {vs 3,203; -15.17%}
Monthly Retail TRx Market Share: 24.58% vs 24.03% --- ATH
Monthly Retail NRx Market Share: 26.25% vs 25.31% --- ATH
Monthly Retail Refills Market Share: 23.56% vs 23.28% --- ATH
Baker Bros;
Just keeping track of major changes in AMRN via 13F releases as of 31/12/2016;
Baker Bros increased their holdings by 1,539,032 shares
Ascend Capital by 374,719
Blackrock by 1,133,603 shares
Clearbridge by 607,440
Consonance Capital by 400,000
Deutsche Bank by 278,013
Goldman Sachs by 154,898
J.Goldman by 781,200
Millennium Management by 1,590,436
Morgan Stanley by 193,634
Oracle Investment by 1,840,728
Renaissance Technologies by 335,400
State of Tennessee by 410,200
Susquehanna Group by 403,613
As for negative changes major ones are:
Acadian Asset Management decreased their holdings by 1,684,434
Broadfin Capital by 525,400
Highland Capital by 738,000
Sold Out;
Franklin Resources by 4,649,958
Perceptive Advisors by 1,622,280
Thx JL for the clarification
Renaissance Technologies;
Isn't this the fund of Janet's Hubby?!
They just increased their allocation in AMRN by 335,000 shares
On another note, BlackRock increased their position as of 31/12/2016 by 1,113,000 shares.
Looking forward for the full 13F release in the near future
Scripts Update for Week Ending 03/02
V
TRx: 19,462 {vs 19,222; +1.25%} Sector +0.98%
NRx: 8,278 {vs 8,283; -0.06%} Sector +0.75%
Ref: 11,184 {vs 10,939; +2.24%} Sector +1.13%
GenL
TRx: 56,056 {vs 55,438; +1.11%}
NRx: 21,617 {vs 21,326; +1.36%}
L
TRx: 1,683 {vs 1,790; -5.98%}
NRx: 584 {vs 642; -9.03%}
V TRx Market Share: 25.21% vs 25.14% -- ATH
V NRx Market Share: 27.16% vs 27.38%
V Ref Market Share: 23.94% vs 23.68% -- ATH
Scripts Update -- Typo Mistake
V
TRx: 19,222 {vs 18,940; +1.49%} Sector +0.92%
NRx: 8,283 {vs 8,035 (not 7,035); +3.09%} Sector +2.30% -- ATH
Ref: 10,939 {vs 10,905; +0.31%} Sector +0.03%
Scripts Update for Week Ending 27/01
ATH Across The Board in terms of Market Share
V
TRx: 19,222 {vs 18,940; +1.49%} Sector +0.92%
NRx: 8,283 {vs 7,035; +3.09%} Sector +2.30% -- ATH
Ref: 10,939 {vs 10,905; +0.31%} Sector +0.03%
GenL
TRx: 55,438 {vs 55,121; +0.58%}
NRx: 21,326 {vs 20,928; +1.90%}
L
TRx: 1,790 {vs 1,692; +5.79%}
NRx: 642 {vs 607; +5.77%}
V TRx Market Share: 25.14% vs 25.00% -- ATH
V NRx Market Share: 27.38% vs 27.17% -- ATH
V Ref Market Share: 23.68% vs 23.61% -- ATH
Data Update
sorry all, not able to update data today as I'm out of the office
invest
You shouldn't be worried.
The past 2 weeks, NRx has been increasing more than TRx and it will take time for all new ones to start refill their V, so it will go in parallel in future script numbers
Scripts Update for Week Ending 20/01
ATH Across The Board in terms of Market Share
Great Numbers for a short week “MLK”
V
TRx: 18,940 {vs 18,705; +1.26%} Sector -1.06%
NRx: 8,035 {vs 7,646; +5.09%} Sector -0.54%
Ref: 10,905 {vs 11,059; -1.39%} Sector -1.40%
GenL
TRx: 55,121 {vs 56,114; -1.77%}
NRx: 20,928 {vs 21,477; -2.56%}
L
TRx: 1,692 {vs 1,749; -3.26%}
NRx: 607 {vs 608; -0.16%}
V TRx Market Share: 25.00% vs 24.43% -- ATH
V NRx Market Share: 27.17% vs 25.72% -- ATH
V Ref Market Share: 23.61% vs 23.61% -- = ATH
Analysis: Quarter vs Quarter & Full Year 2016
Q4-2016 vs. Q4-2015 (Retail + Institutional Data)
V
TRx: 256,371 {vs 180,900; +41.72%} – Sector -3.65% --- ATH
Gen L
TRx: 839,790 {vs 915,226; -8.24%}
L
TRx: 31,147 {vs 73,944; -57.88%}
V Q4-2016 Retail + Inst. TRx Market Share: 22.74% vs 15.46% in Q4-2015
Q4-2016 vs. Q3-2016 (Retail + Institutional Data)
V
TRx: 256,371 {vs 236,767; +8.28%} – Sector -0.16% --- ATH
Gen L
TRx: 839,790 {vs 854,237; -1.69%}
L
TRx: 31,147 {vs 38,092; -18.23%}
V Q4-2016 Retail + Inst. TRx Market Share: 22.74% vs 20.97% in Q3-2016
1Y-2016 vs. 1Y-2015 (Retail + Institutional Data)
V
TRx 1Y-2016 vs 1Y-2015 +48.88% – Sector -0.14%
Gen L
TRx 1Y-2016 vs 1Y-2015 -0.98%
L
TRx 1Y-2016 vs 1Y-2015 -60.23%
V 1Y-2016 Retail + Inst. TRx Market Share: 19.94% vs 13.38% in 1Y-2015 -- ATH
Total Monthly Retail + Institutional Data December-2016
ATH ACROSS THE BOARD
V
TRx: 90,234 {vs 83,218; +8.43%} -- Sector +5.00% -- ATH
(Inst # 3,955 vs 3,155; +25.36% -- Inst. Sector +9.41% -- ATH)
(Inst Market Share 14.77% vs 12.89% -- ATH)
Refills: 56,814 {vs 52,573; +8.07%} – Sector +5.16% -- ATH
Gen L
TRx: 285,408 {vs 274,120; +4.12%}
(Inst # 21,538 vs 19,990; +7.74%)
L
TRx: 10,208 {vs 10,136; +0.71%}
(Inst # 1,279 vs 1,325; -3.47%)
V Monthly Retail + Inst. TRx Market Share: 23.39% vs 22.65% --- ATH
V Monthly Retail + Inst. NRx Market Share: 25.31% vs 24.30% --- ATH
V Monthly Retail + Inst. Ref Market Share: 22.38% vs 21.78% --- ATH
cbb,
their projection does not include reduce it success nor worldwide deals / partnership...thats why it can be seen as very conservative projection
Report by H.C.Wainwright Update 23-Jan-2017
Price Target $10. We anticipate a revival in investor interest and share value through 2017. This is the year when our bull thesis on Amarin is likely to start coming into play. Now, as we reach the final year of the six-year REDUCE-IT outcome study (last cardiovascular event set to occur near YE17), it is worthwhile to highlight again the potential drivers of value in the year ahead:
(1) continued Vascepa growth in TRx and NRx, expected to put company in cash flow-positive territory this year;
(2) REDUCE-IT second interim readout on tap for before 3Q17 (see our analysis below);
(3) REDUCE-IT topline data in 2018 (we expect a statistically significant win).
We believe that ahead of and through these catalysts, and in anticipation of REDUCE-IT topline, Amarin shares are likely to start trending upward, as old investors familiar with the story finally start re-engaging, following their outflow after the disappointing ANCHOR AdCom in Oct 2013 and their long wait for value-driving developments since. We advise our audience to position ahead of this potential revival trend, and reiterate our Buy rating and a $10 price target.
REDUCE-IT second interim look has higher probability of success than first interim. In terms of the key REDUCE-IT study, the second interim study is on tap for mid-2017........From our perspective, the tracking of guidance to our projections dictates that pooled placebo and treatment are exactly in line with expectations of the desired risk reduction.
Boding well for REDUCE-IT: independent study shows early initiation of EPA resulted in 11% absolute risk reduction in MACE as well as a one year mortality benefit compared to statin alone in patients with acute coronary syndromes.......
Link:
https://drive.google.com/file/d/0B57g27wC5ShheER1SENPT2Z0Z0k/view?usp=sharing
SunTrust Update: 20-Jan-2017
AMRN raised $30M in 3.50% convertible debt ($3.89 strike) due in 2047 through a private placement. AMRN intends to use ~$15M to repo its 2032 Convertible Notes, with ~$14M for general corporate & working capital purposes. We maintained our sales & expenses, with no change to our ’17 sales ($172M vs. AMRN’s $155-$165M range) & LPS of ($0.14). In the out years, our EPS declines by ~$0.01 per year, with no meaningful impact on our DCF. The next catalyst is the 2nd REDUCE-IT interim analysis in 3Q17 (80% of events should be reached in 1H17). Reiterate our Buy & $6PT, based on our DCF analysis.
Link:
https://drive.google.com/file/d/0B57g27wC5ShhVGxWejV4NHUtX1U/view?usp=sharing
jfm
exactly, that's why i said "need to see and watch the data (full ones) for a couple of weeks for confirmation"
Cheers
BB
It is too early to say that. Don't forget that this is the 1st full week after Christmas and New Year short ones. For sure we are beating the market, need to see and watch the data (full ones) for a couple of weeks for confirmation
Debt Restructuring 8K
https://www.sec.gov/Archives/edgar/data/897448/000119312517013610/d332641d8k.htm
At any time after the issuance of the 2017 Notes and prior to the close of business on the second business day immediately preceding January 15, 2047, holders may exchange their 2017 Notes for American Depositary Shares of the Company (“ADS”) at their option and at the exchange rate described below. If prior to January 19, 2021, a make-whole fundamental change (as defined in the Indenture) occurs and a holder elects to exchange its 2017 Notes in connection with such make-whole fundamental change, such holder may be entitled to an increase in the exchange rate as described in the Indenture.
The Issuer may elect at its option to cause all or any portion of the 2017 Notes to be mandatorily exchanged in whole or in part at any time prior to the close of business on the business day preceding January 15, 2047 if the Daily VWAP (as defined in the Indenture) equals or exceeds 130% of the Exchange Price then in effect (which quotient equals approximately $5.05 on the date hereof) for at least 20 VWAP Trading Days (as defined in the Indenture) in any 30 consecutive VWAP Trading Day period. The Issuer may only exercise its optional exchange rights upon satisfaction of specified equity conditions, including that the ADSs issuable upon exchange of the 2017 Notes be eligible for resale without registration by non-affiliates and listed on The NASDAQ Global Market, its related exchanges or the New York Stock Exchange. If the Issuer elects to exercise its optional exchange rights on or prior to January 19, 2021, each holder whose 2017 Notes are exchanged may upon exchange receive a specified number of additional ADSs as set forth in the Indenture.
Scripts Update for Week Ending 13/01
ATH Across The Board in terms of Market Share
V
TRx: 18,705 {vs 17,880; +4.61%} Sector +2.07%
NRx: 7,646 {vs 6,533; +17.04%} Sector +11.82%
Ref: 11,059 {vs 11,347; -2.54%} Sector -3.28%
GenL
TRx: 56,114 {vs 55,247; +1.57%}
NRx: 21,477 {vs 19,406; +10.67%}
L
TRx: 1,749 {vs 1,888; -7.36%}
NRx: 608 {vs 649; -6.32%}
V TRx Market Share: 24.43% vs 23.84%-- ATH
V NRx Market Share: 25.72% vs 24.57% -- ATH
V Ref Market Share: 23.61% vs 23.43% -- ATH
DATA COMPARISON Q4 (2016vs2015) & Q4-16 vs Q3-16
Q4-2016 vs. Q4-2015 (Retail Data ONLY)
V
TRx: 246,127 {vs 168,758; +45.85%} – Sector -1.16% --- ATH
Gen L
TRx: 779,970 {vs 847,586; -7.98%}
L
TRx: 27,020 {vs 49,125; -45.00%}
V Q4-2016 Retail ONLY TRx Market Share: 23.37% vs 15.84% in Q4-2015 --- ATH
Q4-2016 vs. Q3-2016 (Retail ONLY Data)
V
TRx: 246,127 {vs 225,955; +8.93%} – Sector +1.36% --- ATH
Gen L
TRx: 779,970 {vs 784,750; -0.61%}
L
TRx: 27,020 {vs 28,315; -4.57%}
V Q4-2016 Retail ONLY TRx Market Share: 23.37% vs 21.75% in Q3-2016
Total Monthly Retail ONLY Data December-2016
ATH ACROSS THE BOARD
V
TRx: 86,279 {vs 80,063; +7.76%} – Sector +4.69% -- ATH
NRx: 33,420 {vs 30,645; +9.06%} – Sector +4.69% -- ATH
Ref: 52,859 {vs 49,418; +6.96%} – Sector +4.68% -- ATH
Gen L
TRx: 263,870 {vs 254,130; +3.83%}
NRx: 95,402 {vs 92,263; +3.40%}
L
TRx: 8,929 {vs 8,811; +1.34%}
NRx: 3,203 {vs 3,199; +0.13%}
Monthly Retail TRx Market Share: 24.03% vs 23.34% --- ATH
Monthly Retail NRx Market Share: 25.31% vs 24.30% --- ATH
Monthly Retail Refills Market Share: 23.28% vs 22.78% --- ATH
Scripts Update for Week Ending 06/01
V
TRx: 17,880 {vs 17,984; -0.58%} Sector -1.12%
NRx: 6,533 {vs 5,973; +9.38%} Sector +9.14%
Ref: 11,347 {vs 12,011; -5.53%} Sector -5.97%
GenL
TRx: 55,247 {vs 55,957; -1.27%}
NRx: 19,406 {vs 17,770; +9.21%}
L
TRx: 1,888 {vs 1,923; -1.82%}
NRx: 649 {vs 618; +5.02%}
V TRx Market Share: 23.84% vs 23.71% -- (ATH=24.27%)
V NRx Market Share: 24.57% vs 24.52% -- (ATH=25.65%)
V Ref Market Share: 23.43% vs 23.32% -- ATH
CANTOR BY ZUM
Thanks Zum for posting the update. Just realized there is one :):)
I guess the most important part mentioned is the following:
Russo noted, “We met with management briefly at a conference in San Francisco..... In addition, management noted that the multitude of secondary endpoints in the REDUCE-IT outcomes trial should not be overlooked. Potential benefit seen in large subpopulations such as diabetics, coupled with a very well-tolerated safety profile, could meaningfully expand the value proposition beyond treatment for high triglycerides, in our view.”
The title is quite interesting too. It states "REDUCE-IT Not Binary - May Highlight Add'l Subpopulations"
Link:
https://drive.google.com/file/d/0B1gB2YESBJV7NWF3RUV3WUxzc0U/view?usp=sharing
Suntrust Update Jan-2017:
https://drive.google.com/open?id=0B57g27wC5ShhMll5c1MtQXczeUk
Cantor Update Jan-2017:
https://drive.google.com/open?id=0B57g27wC5ShhMXpFcjRVM29fX2c
GOED
How come Amarin is not a member in this organization?
Scripts Update for Week Ending 23/12
ATH Across the Board in terms of Market Share
V
TRx: 19,847 {vs 19,814; +0.17%} Sector -1.30%
NRx: 7,944 {vs 7,939; +0.06%} Sector -1.78%
Ref: 11,903 {vs 11,875; +0.24%} Sector -1.01%
GenL
TRx: 59,949 {vs 61,043; -1.79%}
NRx: 22,275 {vs 23,850; -2.52%}
L
TRx: 1,991 {vs 2,008; -0.85%}
NRx: 748 {vs 739; +1.22%}
V TRx Market Share: 24.27% vs 23.91% -- ATH
V NRx Market Share: 25.65% vs 25.18% -- ATH
V Ref Market Share: 23.42% vs 23.13% -- ATH
HAPPY NEW YEAR EVERYONE, ALL THE BEST WISHES FOR THE COMING YEAR
Scripts Update for Week Ending 16/12
V
TRx: 19,814 {vs 20,076; -1.31%} Sector -1.19%
NRx: 7,939 {vs 8,128; -2.33%} Sector -1.38%
Ref: 11,875 {vs 11,948; -0.61%} Sector -1.07%
GenL
TRx: 61,043 {vs 61,659; -1.00%}
NRx: 22,850 {vs 23,084; -1.01%}
L
TRx: 2,008 {vs 2,128; -5.64%}
NRx: 739 {vs 757; -2.38%}
V TRx Market Share: 23.91% vs 23.94%
V NRx Market Share: 25.18% vs 25.42%
V Ref Market Share: 23.13% vs 23.02% -- ATH
FFS,
it was a typo mistake. Bio wanted to say 3.50 and i corrected that on teh board to which things were clear after
Posts #96653 & #96697
Cheers
Total Monthly Retail + Institutional Data November-2016
V
TRx: 83,218 {vs 82,919; +0.36%} -- Sector -1.74% -- ATH
(Inst # 3,155 vs 3,134)
Gen L
TRx: 274,120 {vs 280,262; -2.19%}
(Inst # 19,990 vs 18,292)
L
TRx: 10,136 {vs 10,803; -6.17%}
(Inst # 1,325 vs 1,523)
V Monthly Retail + Inst. TRx Market Share: 22.65% vs 22.17% --- ATH
V Monthly Retail + Inst. NRx Market Share: 24.30% vs 23.51% --- ATH
V Monthly Retail + Inst. Ref Market Share: 21.78% vs 21.46% --- ATH
Scripts Update for Week Ending 09/12
Finally iHub is working again. Most know the scripts by now from ST, but below the usual Friday post :)
V
TRx: 20,076 {vs 19,908; +0.84%} Sector -1.55% -- ATH
NRx: 8,128 {vs 7,620; +6.67%} Sector +3.12% -- ATH
Ref: 11,948 {vs 12,288; -2.77%} Sector -4.23%
GenL
TRx: 61,659 {vs 63,081; -2.25%}
NRx: 23,084 {vs 22,636; +1.98%}
L
TRx: 2,128 {vs 2,197; -3.14%}
NRx: 757 {vs 745; +1.61%}
V TRx Market Share: 23.94% vs 23.37% -- ATH
V NRx Market Share: 25.42% vs 24.58% -- ATH
V Ref Market Share: 23.02% vs 22.68% -- (ATH=23.07%)
US files first charges in generic drug price-fixing probe: CNBC Report
The U.S. filed its first charges in a generic drug price-fixing probe on Wednesday, according a report.
Shares of Teva Pharmaceutical Industries, Mylan, Perrigo, other related stocks and the iShares Nasdaq Biotechnology ETF fell after Bloomberg published headlines of the charges. The headlines did not mention specific companies however.
The Justice Department did not immediately return CNBC's request for comment.
This is a developing story. Please check back for updates.